Menu
← Oncology Approval Tracker
FDA DECISION ·
Aukelso
denosumab-kyqq · Biocon Biologics
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Xgeva biosimilar for preventing skeletal complications in multiple myeloma or solid tumor bone metastases, treating giant cell tumor of bone in eligible adults and skeletally mature adolescents, and treating malignancy-related hypercalcemia refractory to bisphosphonates.
LAMPGEN ANALYSIS
Why it matters
This oncology-dose denosumab approval adds a biosimilar option for the labeled Xgeva uses.
What research teams should watch
Keep the prevention and bone loss pathways separate in inventory, orders, and patient-facing instructions.
PRIMARY RECORDS